文献速递病毒性肝炎细菌感染、耐药与抗菌药物医院感染防控

直接抗病毒药物与针具获取联合药物辅助治疗在注射吸毒人群中丙型肝炎感染的成本效果

Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究采用数学模型模拟注射吸毒人群中丙型肝炎病毒(HCV)的进展及相关后果,评估直接抗病毒药物(DAA)与药物辅助治疗联合针具获取项目(MAT+)不同覆盖水平的成本效果。从卫生部门视角看,仅DAA最具成本效果;而纳入刑事司法系统相关成本后,DAA联合MAT+成为最具成本效果的干预。

要点

  • 卫生部门视角下DAA联合MAT+覆盖率越高ICER越高。
  • 社会视角下DAA20%联合MAT+80%最具效果且节省成本。

核心结论

  • 仅考虑卫生部门成本时,单独DAA是最具成本效果的干预。
  • 纳入刑事司法系统相关成本后,DAA与MAT+联合实施成为最具成本效果的干预。

研究设计与样本

  • 分配效率研究,结合两个先前验证的模拟模型,模拟注射吸毒人群中HCV进展及相关后果。
  • 分析从卫生部门和社会视角进行,时间跨度15年,贴现率3%。

主要发现

  • 卫生部门视角下(排除刑事司法系统相关成本),4种策略位于成本效率前沿。
  • 社会视角下(包括刑事司法系统相关成本),DAA20%联合MAT+80%是最有效干预且节省成本。

临床怎么用

  • 在注射吸毒人群中,选择HCV干预策略时需考虑是否纳入刑事司法系统相关成本。
  • 若仅关注卫生部门成本,优先考虑单独DAA;若考虑社会成本,DAA联合MAT+更具成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are too many plausible permutations and scale-up scenarios of combination hepatitis C virus (HCV) interventions for exhaustive testing in experimental trials. Therefore, we used a computer simulation to project the health and economic impacts of alternative combination intervention scenarios for people who inject drugs (PWID), focusing on direct antiviral agents (DAA) and medication-assisted treatment combined with syringe access programs (MAT+). METHODS: We performed an allocative efficiency study, using a mathematical model to simulate the progression of HCV in PWID and its related consequences. We combined 2 previously validated simulations to estimate the cost-effectiveness of intervention strategies that included a range of coverage levels. Analyses were performed from a health-sector and societal perspective, with a 15-year time horizon and a discount rate of 3%. RESULTS: From a health-sector perspective (excluding criminal justice system-related costs), 4 potential strategies fell on the cost-efficiency frontier. At 20% coverage, DAAs had an incremental cost-effectiveness ratio (ICER) of $27 251/quality-adjusted life-year (QALY). Combinations of DAA at 20% with MAT+ at 20%, 40%, and 80% coverage had ICERs of $165 985/QALY, $325 860/QALY, and $399 189/QALY, respectively. When analyzed from a societal perspective (including criminal justice system-related costs), DAA at 20% with MAT+ at 80% was the most effective intervention and was cost saving. While DAA at 20% with MAT+ at 80% was more expensive (eg, less cost saving) than MAT+ at 80% alone without DAA, it offered a favorable value compared to MAT+ at 80% alone ($23 932/QALY). CONCLUSIONS: When considering health-sector costs alone, DAA alone was the most cost-effective intervention. However, with criminal justice system-related costs, DAA and MAT+ implemented together became the most cost-effective intervention.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Stevens ER, Nucifora KA, Hagan H, et al. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population. Clin Infect Dis. 2020. PMID: 31400755. doi:10.1093/cid/ciz726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。